Full Breakdown
Small-Cap Biotech Stocks Under $10: ARS Pharmaceuticals’ Needle-Free Epinephrine and Fennec Pharmaceuticals’ PEDMARK Surge
7/18/2026, 8:02:54 PM
Core Developments
- ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is advancing *neffy*, a nasal-spray epinephrine product intended to treat anaphylaxis without a needle. The company announced a leadership transition on July 8, naming Donn Casale as chief executive officer effective July 7. A July 24 update reported no new payer formulary decisions for neffy during the July 1 review cycle, prompting the firm to pursue additional payer negotiations and a retail cash-option for uninsured patients.
- Fennec Pharmaceuticals Inc. (NASDAQ: FENC) reported Q1 2026 net revenues of $15.1 million for its PEDMARK® sodium thiosulfate injection, a 73 % year-over-year increase that beat consensus estimates and generated a modest positive EPS of $0.01. The company is expanding PEDMARK’s indication from pediatric oncology to the adolescent-and-young-adult (AYA) population, supported by NCCN guideline endorsement and an upcoming presentation at the 2026 ASCO Annual Meeting.
Background & Market Context
Small-cap equities trading below $10 have attracted investors seeking >200 % upside, provided they possess market capitalizations above $2 billion and credible growth catalysts. Morningstar’s small-cap index outperformed the broader market in 2026, and analysts have highlighted diversification benefits relative to the concentration of mega-cap holdings in the S&P 500.
Key Figures & Leadership
- Richard Lowenthal – co-founder and former CEO of ARS, departed the company effective July 6.
- Donn Casale – former president of ARS, appointed CEO and board member on July 7; previously chief commercial officer at Dynavax Technologies, where he helped grow HEPLISAV-B revenue to >$300 million.
- Fennec’s executive team (unnamed in the sources) is steering the commercial rollout of PEDMARK and its international licensing strategy.
Data & Statistics
- ARS shares trade around $7, down 6.23 % on the day of the leadership announcement; market cap exceeds $2 billion.
- Fennec shares closed at $9.93 on May 22, 2026, with a market cap of $283.8 million. Q1 2026 revenue rose 73 % YoY to $15.1 million; EPS of $0.01 beat the consensus loss estimate of –$0.02. The company’s trailing twelve-month net loss is $8.38 million, with a P/E of –40.71.
Why It Matters to Investors
- Neffy could capture a sizable share of the emergency-allergy market by offering a needle-free alternative, potentially increasing adherence among patients who avoid injections.
- PEDMARK enjoys orphan-drug exclusivity, patent protection through 2039, and a first-in-class FDA designation, positioning it as a premium therapy in a market with limited competition. Expansion into the AYA segment and international licensing could lift annual revenues toward $500-800 million by 2030.
Official Statements & Responses
- ARS announced that “no new coverage decisions or commercial formulary additions had been issued for neffy during the July 1 review cycle,” and pledged to continue working with payers while offering a retail cash option.
- Fennec’s earnings release highlighted “strong Q1 2026 revenue growth and a surprise to profitability,” attributing the performance to successful commercial execution and expanding adoption across new accounts.
Criticism & Opposition
- Payer uncertainty: The lack of new formulary listings may delay neffy’s market penetration, and physicians must be convinced of its efficacy across varied nasal conditions.
- Single-product risk: Fennec remains heavily dependent on PEDMARK; any manufacturing issue, competitive entry, or reimbursement change could materially affect financial results. The company’s negative net income and cash-burn profile underscore this vulnerability.
Verbatim Quotes
- “Effective July 6, company co-founder and Chief Executive Officer Richard Lowenthal was no longer employed by the business.” — ARS Pharmaceuticals press release
- “Donn Casale, who had been serving as president, was appointed the new chief executive officer and a member of the company’s board of directors beginning July 7.” — ARS Pharmaceuticals press release
- “Casale previously served as Chief Commercial Officer at Dynavax Technologies, where he played an important role in expanding annual revenue for HEPLISAV-B, a hepatitis B vaccine, to more than $300 million.” — ARS Pharmaceuticals filing
- “Foremost among these is its regulatory status as the first and only FDA-approved sodium thiosulfate (STS) formulation specifically designed to reduce cisplatin-induced ototoxicity.” — Fennec product description
Conflicting Reports & Gaps
- ARS reports no new formulary decisions for neffy, yet the timeline for future coverage expansions remains unspecified.
- Fennec’s outlook relies on projected international approvals (e.g., Japan) that have not yet been granted, leaving the magnitude of future revenue uncertain.
What’s Next
- ARS will continue payer negotiations and monitor retail cash-option uptake, with an implied goal of securing formulary placements in the coming quarters.
- Fennec plans to present new AYA clinical data at the 2026 ASCO Annual Meeting and seeks regulatory approval in Japan, which could further broaden PEDMARK’s addressable market.
